(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.65%.
Sellas Life Sciences Group's earnings in 2025 is -$25,942,000.On average, 4 Wall Street analysts forecast SLS's earnings for 2025 to be -$38,131,787, with the lowest SLS earnings forecast at -$40,482,084, and the highest SLS earnings forecast at -$35,895,444. On average, 4 Wall Street analysts forecast SLS's earnings for 2026 to be -$41,009,121, with the lowest SLS earnings forecast at -$51,649,556, and the highest SLS earnings forecast at -$29,912,870.
In 2027, SLS is forecast to generate -$24,457,332 in earnings, with the lowest earnings forecast at -$36,294,282 and the highest earnings forecast at -$11,965,148.